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Abstract
Background Carcinoid syndrome, a rare condition in patients with neuroendocrine tumours, characterised by flushing and 
diarrhoea, severely affects patients’ quality of life. The current carcinoid syndrome standard of care includes somatostatin 
analogues, but some patients experience uncontrolled symptoms despite somatostatin analogue therapy. Telotristat ethyl is 
a novel treatment approved by the European Medicines Agency (EMA) and US FDA that significantly reduces bowel move-
ment frequency in patients with uncontrolled carcinoid syndrome.
Objective We developed a model to evaluate the 5-year budget impact of introducing telotristat ethyl to standard care in 
Swedish patients with uncontrolled carcinoid syndrome.
Methods Treatment response in the 12-week phase III TELESTAR trial (NCT01677910) informed telotristat ethyl efficacy; 
subsequently, health states were captured by a Markov model using 4-week cycles. TELESTAR open-label extension data 
informed telotristat ethyl discontinuation. The number of treatment-eligible patients was estimated from literature reviews 
reporting the prevalence, incidence and mortality of carcinoid syndrome. A Swedish database study informed real-world 
costs related to carcinoid syndrome and carcinoid heart disease costs. Telotristat ethyl market share was assumed to increase 
annually from 24% (year 1) to 70% (year 5).
Results Over the 5-year model horizon, 44 patients were expected to initiate telotristat ethyl treatment. The cumulative net 
budget impact of adding telotristat ethyl to current standard of care was €172,346; per-year costs decreased from €66,495 
(year 1) to €29,818 (year 5). Increased drug costs from adding telotristat ethyl were offset by reduced costs elsewhere.
Conclusions The expected budget impact of adding telotristat ethyl to the standard of care in Sweden was relatively low, 
largely because of the rarity of carcinoid syndrome.
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Key Points for Decision Makers 
The expected 5-year budget impact of introducing tel-
otristat ethyl to the standard of care in Swedish patients 
with uncontrolled carcinoid syndrome was relatively low 
(€172,346), largely because of the rarity of carcinoid 
syndrome.
Per-year costs decreased from €66,495 (year 1) to 
€29,818 (year 5).
Increased treatment costs from adding telotristat ethyl 
were offset by reduced costs for other aspects of patient 
care.
 K. Fust et al.
1 Introduction
Carcinoid syndrome (CS) is a rare but serious condition 
that develops in some patients with neuroendocrine tumours 
(NETs) [1–3]. Studies from the USA have estimated the 
prevalence of NETs to range between 0.035 and 0.048% [4, 
5]. Secretion of vasoactive peptides and amines by some 
NETs, including serotonin, results in the characteristic 
symptoms of CS, such as cutaneous flushing, diarrhoea 
and wheezing [1]. CS develops most commonly in patients 
with small intestinal NETs and hepatic metastases [3, 6] and 
less commonly in patients with pancreatic tumours or lung 
NETs; CS can also occur when secretions drain directly from 
tumours into the central circulation [3, 7–9]. Approximately 
6–19% of patients with NETs will develop CS [1–3, 10], and 
20–50% of patients with CS develop carcinoid heart dis-
ease (CaHD) [11]. In CaHD, secretion of serotonin and other 
vasoactive substances can cause the deposition of plaques 
on the right side of the heart, leading to right heart valve 
dysfunction and possible heart failure [12]. CS progression 
and response to treatment can be measured through urinary 
or plasma levels of the serotonin metabolite 5-hydroxyin-
doleacetic acid (5-HIAA) [13, 14], with elevated urinary 
5-HIAA (u5-HIAA) being associated with more severe CS 
and CaHD [15, 16].
The US National Comprehensive Cancer Network guide-
lines and European Neuroendocrine Tumor Society guide-
lines currently recommend somatostatin analogues (SSAs), 
such as lanreotide and octreotide, as treatment for patients 
with CS [17, 18]. These long-acting therapeutics can slow 
tumour progression and, importantly, reduce symptoms of 
CS [19–23]. In patients with particularly severe CS, symp-
tom burden can be further reduced by dose escalation of 
long-acting SSAs and the addition of short-acting SSAs and 
anti-diarrheal therapies to the backbone long-acting SSA 
therapy [8, 18, 24–29]. However, despite SSA therapy, CS 
symptoms can persist in approximately 20–40% of patients 
[24, 28, 30–32], and over 60% experience sustained debili-
tating diarrhoea and flushing [30]. Few options exist for 
patients whose CS symptoms remain uncontrolled despite 
treatment with SSAs. The limited alternative treatment 
options include costly, invasive medical interventions that 
target tumour load and decrease serotonin secretion [30, 33].
Telotristat ethyl (TE), a novel tryptophan hydroxylase 
inhibitor, was approved for the treatment of diarrhoea in 
patients with CS by the European Medicines Agency and US 
Food and Drug Administration in 2017 and by Health Can-
ada and the Australian Therapeutic Goods Administration 
in 2018 [34–37]. TE has been shown to reduce daily bowel 
movement frequency in patients whose CS diarrhoea symp-
toms are inadequately controlled by SSAs, subsequently 
improving health-related quality of life when used alongside 
the current standard of care [38, 39]. Treatment guidelines 
in the USA were recently updated to include TE as a treat-
ment option when CS symptoms are poorly controlled [18].
The high healthcare cost of CS, particularly for patients 
with CS that is uncontrolled by the current standard of care, 
presents a healthcare, societal, and patient burden. A 2018 
Swedish study found the cost per patient with controlled CS 
over an 8-month period to be €15,500, rising to €21,700 per 
patient with uncontrolled CS [33]. Furthermore, CS symp-
toms can be debilitating for patients and have a marked 
impact on health-related quality of life [22, 40–42]; diar-
rhoea and flushing, in particular, have been associated with 
reduced physical functioning, increased pain, sleep distur-
bance, depression and anxiety [41].
TE has been approved for reimbursement by the Swed-
ish Dental and Pharmaceutical Benefits Agency (TLV) [43], 
but the affordability of using TE in combination with SSA 
therapy has not yet been demonstrated at the regional level. 
The aim of this study was to estimate the 5-year budget 
impact on the Swedish healthcare system of using TE in 
combination with SSAs, compared with using SSAs only, 
in patients with inadequately controlled CS. To investigate 
this, we created a budget impact model, taking into account 
the drug acquisition cost and all healthcare costs associated 
with TE treatment.
2  Methods
2.1  Budget Impact Model
Base-case model analyses were performed from the perspec-
tive of the Swedish healthcare system and included direct 
healthcare costs only. The time horizon of the model analysis 
was 5 years (2018–2022). This analysis compared two sce-
narios: (1) a ‘world-without TE’ scenario in which only SSA 
therapy was available and (2) a ‘world-with TE’ scenario in 
which TE 250 mg was available in addition to SSA therapy. 
In the model, the size of the target population and the num-
ber of patients initiating treatment were estimated. A deci-
sion tree and Markov model were then used to estimate the 
intensity of symptoms and the associated healthcare costs.
2.1.1  Population and Market Share
The target population was patients with CS inadequately 
controlled by SSA therapy. The number of eligible incident 
cases for years 1–5 and the number of prevalent cases for 
year 1 were estimated using data from systematic and tar-
geted literature reviews (Table 1) [4, 5, 26, 44–47]. Figure 1 
demonstrates how these data were used to estimate incident 
and prevalent cases, with the resulting estimates shown in 
Table 2. For years 2–5, the number of prevalent cases was 
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calculated by the model as the patients continuing from pre-
vious years who had not died. Ten incident patients were 
estimated to be eligible for TE therapy in each year of the 
analysis (based on incidence estimates in Table 1). Addition-
ally, 72 prevalent cases were eligible for therapy in year 1. 
Prevalent patients were assumed to initiate TE treatment in 
year 1 only.
As SSAs are the current standard of care for CS and for 
some stages of NETs, all patients were assumed to have 
received SSA treatment (lanreotide or octreotide) in both 
the world-with TE and world-without TE scenarios [48]. In 
the SSA + TE arm, both prevalent and incident cases were 
considered eligible to commence treatment with TE 250 mg 
in year 1 (2018), whereas only incident cases were consid-
ered eligible in years 2–5 (2019–2022) (Table 2). Based on 
the assumption that TE has just been introduced and most 
patients with inadequately controlled disease will receive 
TE, internal forecasting estimates projected that the market 
share of TE would increase annually, from 24% of eligible 
patients in year 1 to 70% in year 5 (Table 2). SSA market 
share did not vary, as TE is to be used in combination with 
SSAs.
2.1.2  Decision Tree and Markov Model Structure
The model structure used to estimate the intensity of symp-
toms, duration of treatment and associated costs had two 
components: a decision tree that tracked the response to 
the initial 12 weeks of TE treatment using data from TEL-
ESTAR, and a Markov model using 4-week (28-day) cycles 
that tracked the longer-term response to treatment for the 
remaining model time horizon (Fig. 2). Adverse events 
reported in TELESTAR were not expected to increase 
healthcare costs significantly or substantially affect patients’ 
quality of life so were not included in the model.
Patients in the ‘SSA Only’ arm who had a durable 
response to SSAs during the initial 12 weeks of treatment 
entered the Markov model in the ‘respond to SSA’ health 
state, whereas the remaining patients in the SSA Only arm 
entered in the ‘inadequate response’ health state. Patients 
within the SSA Only arm were assumed to remain on SSA 
therapies for the entire simulation, regardless of response 
status. In the SSA + TE arm, patients who achieved a dura-
ble response to TE during the initial 12 weeks of treatment 
entered the Markov model in the ‘durable response’ health 
state, whereas patients who did not demonstrate a durable 
response entered in the ‘discontinue TE’ health state (and no 
longer received TE). The inadequate response health state 
captured patients in the SSA + TE arm who did not main-
tain a durable response but still continued to receive TE. 
All health states were stratified by whether the patient had 
CaHD or not, and the model allowed patients to develop 
CaHD as time progressed. Patients could die in any cycle 
while in any of the health states.
2.1.3  Model Inputs
Initial TE treatment efficacy was informed by data from 
the 12-week double-blind treatment period of the phase III 
TELESTAR trial (NCT01677910). A total of 135 patients 
entered the trial and were randomised to one of three study 
arms: TE 500 mg, TE 250 mg, or placebo, each three times 
daily. All patients remained on the dose of SSA therapy that 
they were receiving upon entry. Full details of the TEL-
ESTAR study design and results have been published pre-
viously [38]. For this analyses, a durable response during 
either stage (the initial 12 weeks of treatment or the 4-week 
Markov cycles) was defined as a ≥ 30% reduction in bowel 
movement frequency for ≥ 50% of the time, matching the 
definition used in TELESTAR [38].
The target population for treatment with TE has been 
defined as patients who have not adequately responded to 
SSA treatment. In other words, patients who receive TE 
treatment are not expected to have further symptom reduc-
tion with SSAs alone. Therefore, for the base-case analy-
sis, the proportion of durable responders was assumed 
to be 0% for patients receiving SSA treatment alone. All 
patients in the SSA Only arm entered the Markov model in 
the inadequate response health state and did not ever enter 
into the respond to SSA health state. Within the SSA + TE 
treatment arm, the proportion of patients with a durable 
response attributable to TE after 12 weeks of treatment was 
24.4% (Table 1). This was calculated using data from the 
TELESTAR trial, in which 20 of the 45 (44.4%) patients 
randomised to SSA + TE demonstrated a durable response 
compared with 9 of the 45 (20%) patients randomised to 
SSA + placebo [38].
The 4-week probability of transitioning to the discontinue 
TE health state was set to 0.0321 based on data from the 
open-label extension period of TELESTAR, which was not 
placebo controlled [49]. The probability of transitioning to 
the inadequate response health state was set to 0 under the 
assumption that clinicians would discontinue TE treatment 
if patients stopped showing a durable response to TE. The 
impact of this assumption was tested in sensitivity analyses 
by increasing the probability that patients would transition 
to the inadequate response health state to 0.5, in the situa-
tion where a physician does not discontinue TE in a fragile 
patient even though the patient is not benefiting from treat-
ment, given a lack of alternative options.
To incorporate CaHD into the model, the following assump-
tions were made: an increase in 5-HIAA levels is associated 
with an increase in CaHD incidence; TE reduces 5-HIAA lev-
els regardless of durable response status [38]; and individuals 
with CaHD have an increased risk of death compared with those 
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Table 1  Base-case model inputs
CaHD carcinoid heart disease, CS carcinoid syndrome, IFN interferon, NET neuroendocrine tumour, SSA somatostatin analogue, TE telotristat 
ethyl, u5-HIAA urinary 5-hydroxyindoleacetic acid
a Forecasting assumption based on interviews with healthcare professionals
b Based on a post-hoc analysis of TELESTAR clinical trial data
c Data derived from Kulke et al. [38], in which 20 of 45 (44.4%) patients randomised to SSA + TE demonstrated a durable response, compared 
with 9 of 45 (20%) patients randomised to SSA + placebo; therefore, for the purpose of this model, 24.4% of the response was presumed to be 
attributable to TE
d Values from Lesén et al. [33], which cover an 8-month period, were divided by eight to determine per-month costs
e Annual CaHD incidence was assumed to be 2.96% for patients with 5-HIAA < 300 mmol/24 h [50]
f TE not included in standard of care
Target population selection inputs Value [source]
Total population of Sweden, n 10,223,505 [46]
NETs prevalence, n per 100,000 population 37 [4, 44]
Annual NETs incidence, n per 100,000 population 5.25 [5, 44]
Proportion of patients with intestinal (small bowel) NETs, % 17.2 [5, 44]
 Proportion of intestinal (small bowel) NETs that are grade 1/2, % 91.0 [44, 45]
  Proportion of patients with CS, of those with grade 1/2 intestinal NETs, % 30.0 [26, 44]
Proportion of patients with lung NETs, % 27.0 [5]
 Proportion of lung NETs that are grade 1/2, % 5.4 [45]
  Proportion of patients with CS, of those with grade 1/2 lung NETs, % 5.0 [47]
Proportion of patients with CS that is uncontrolled by SSAs, % 40.0a
CaHD inputs [50] Value
Relative mortality associated with CaHD 2.55
Baseline incidence of CaHD, % 2.96
Relative risk for CaHD development in patients with u5-HIAA levels > 300 µmol/24 h 2.74
 Proportion of TE-treated patients with u5-HIAA levels < 300 µmol/24 h, %b 82.0
 Proportion of placebo-treated patients with u5-HIAA levels < 300 µmol/24 h, %b 55.0
Efficacy inputs for patients receiving TE Value
Proportion of patients treated with TE achieving durable response that is attributed to TE (TELESTAR), % 24.4c
Annual mortality rate for patients with and without CaHD by year of the analysis [51]
Year of analysis Age, years No CaHD With CaHD
1 (2018) 64 0.1455 0.3303
2 (2019) 65 0.1491 0.3375
3 (2020) 66 0.1491 0.3375
4 (2021) 67 0.1491 0.3375
5 (2022) 68 0.1491 0.3375
Medical cost inputs for patients receiving standard of care (SSAs) [33]d
Item Controlled CS, € per month Uncontrolled CS, € per 
month
Incremental cost of 
CaHD, € per  monthe
Medical and surgical interventions 143.60 494.00 170.92
Examinations and imaging 78.78 264.75 87.58
Other outpatient visits 57.84 74.75 2.08
Inpatient admissions 260.13 263.75 32.75
SSAs 1257.88 1521.50 220.50
IFN-α 137.63 83.88 –
Chemotherapy 0.94 5.60 –
Other diarrhoea therapy 1.98 4.11 –
CaHD drug costs – – 1.83
Sum of monthly medical cost inputs for patients receiving standard of care 1938.78 2712.34 515.66
Drug costs for patients receiving SSAs + TEf € per 4 weeks
TE 982.27
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without. Levels of u5-HIAA were informed through analysis of 
data from the TELESTAR clinical trial [38]. The incidence of 
CaHD based on u5-HIAA was calculated using CaHD incidence 
as reported in Bhattacharyya et al. [50], which was the only 
study identified in a systematic literature review examining the 
link between 5-HIAA levels and CaHD incidence (Table 1).
The mean age of the cohort at the start of the simulation 
was assumed to be 64 years based on TELESTAR patient 
characteristics [38]. Relative 5-year survival rates for grade 
1 and 2 tumours located in the intestinal tract were deter-
mined through application of the relative survival rates in 
Korse et al. [45] to the Swedish age-specific mortality rates. 
Total population of Sweden (N=10,223,505) [46]
NET incidence per 100,000 (5.25) [5, 44]
% with intestinal (small bowel) 
NETs (17.2%) [5, 44] % with lung NETs (27.0%) [5]
% of intestinal (small bowel) 
NETs that are G1/G2 (91.0%) 
[44, 45]
% of lung NETs that are G1/G2 
(5.4%) [45]
% of patients with CS, of those 
with G1/G2 intestinal (midgut) 
NETs (30.0%) [26,44]
% of patients with CS, of those 
with G1/G2 lung NETs (5.0%) 
[47]
% with CS uncontrolled by 
SSAs (40.0%)a
% with CS uncontrolled by 
SSAs (40.0%)a
Total number of incident CS cases eligible for treatment with TE
(n=10)
NET prevalence per 100,000, Year 1 only (37) [4, 44]
% with intestinal (small bowel) 
NETs (17.2%) [5, 44] % with lung NETs (27.0%) [5]
% of intestinal (small bowel) 
NETs that are G1/G2 (91.0%) 
[44, 45]
% of lung NETs that are G1/G2 
(5.4%) [45]
% of patients with CS, of those 
with G1/G2 intestinal (midgut) 
NETs (30.0%) [26, 44]
% of patients with CS, of those 
with G1/G2 lung NETs (5.0%) 
[47]
% with CS uncontrolled by 
SSAs (40.0%)a
% with CS uncontrolled by 
SSAs (40.0%)a























Fig. 1  Selection criteria for determining the target population (inci-
dent and prevalent CS cases eligible for treatment with TE), based on 
data from systematic and targeted literature reviews. Data from lit-
erature reviews were used to estimate the target population selection 
inputs as listed in Table 1. Resulting estimates used in the model are 
shown in (parentheses), with the relevant sources in [brackets]. aFore-
casting assumption based on interviews with healthcare professionals. 
CS carcinoid syndrome, G1/G2 grade 1/grade 2, NET neuroendocrine 
tumour, SSA somatostatin analogue, TE telotristat ethyl
Table 2  Forecast base-case 
eligible population and market 
share assumptions for the 
world-without TE and world-
with TE scenarios over 5 years
CS carcinoid syndrome, SSA somatostatin analogue, TE telotristat ethyl
Prevalence and incidence of uncontrolled CS was assumed to be the same for scenarios both with and with-
out TE; values have been rounded to the nearest whole number
a Total cases decreases from year 3 as the rate of mortality for patients with prevalent CS is higher than the 
incidence of new patients, based on mortality estimates in Table 1
b Prevalent and incident cases do not sum to 78 due to rounding
Year 1 (2018) Year 2 (2019) Year 3 (2020) Year 4 (2021) Year 5 (2022)
Population
 Prevalent cases 72 74 71 68 66
 Incident cases 10 10 10 10 10
 Total  casesa 82 84 81 79b 76
Market share
 World-without TE scenario
  SSAs only, % 100 100 100 100 100
 World-with TE scenario
  SSA + TEs, % 24 52 58 60 70
  SSAs only, % 76 48 42 40 30
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For the base case, the mortality risk associated with CaHD 
was calculated using data from Westberg et al. [51]. Base-
case model inputs for mortality risk are shown in Table 1.
2.1.4  Cost Inputs
The unit cost of TE in Swedish krona (SEK) (10,100.00) 
[43] was converted to € using the European Central Bank 
conversion rate as of 28 November 2018 (€1 = SEK10.2823). 
Therefore, the unit cost of TE in Sweden is approximately 
€11.69 per 250 mg pill, cumulating in a total cost of €982.27 
over 4 weeks (three pills per day). Patients in the SSA + TE 
arm during the initial treatment period and those in the dura-
ble response and inadequate response to TE health states 
within the Markov model incurred this cost.
Real-world CS and CaHD-related costs, including health-
care resource use (frequency per month), drug acquisition 
and SSA dosage (cost of average dose) for patients with 
controlled and uncontrolled CS were obtained from a ret-
rospective Swedish database study [33] (Table 1). A num-
ber of symptoms not limited to diarrhoea may contribute 
to cost differences between responders and non-responders 
in the model. The costs associated with patients with con-
trolled CS were assigned to the respond to SSA and dura-
ble response to TE health states. The costs associated with 
patients with uncontrolled CS were assigned to all remain-
ing non-responder health states. Incremental costs for CaHD 
were determined by calculating the difference in monthly 
costs between patients with and without CaHD. The cost 
year for all model inputs was 2015, except for the Swedish 
total population size and TE unit cost, which used actual 
values as of reimbursement approval by the TLV in 2018.
2.2  Deterministic Sensitivity Analyses
Deterministic (one-way) sensitivity analyses were conducted 
to assess the impact of model parameters. Model parameters 
were varied using 95% confidence intervals (CIs) or plausi-
ble ranges as reported in the published literature. When the 
published study did not report 95% CIs or ranges, plausible 
ranges were specified or informed by clinical expert opin-
ion, obtained through interviews with experts identified as 
knowledgeable about NET management and economic mod-
els. Ranges for inputs included in the sensitivity analyses are 
shown in electronic supplementary material 1.
3  Results
3.1  Base‑Case Analysis
3.1.1  Number of Patients Treated
Based on the assumed TE market share and number of CS 
cases in the base population, approximately 44 patients 
would initiate TE therapy during the 5-year time horizon 
(Table 3). Because prevalent patients were assumed to ini-
tiate TE treatment in year 1 only, the number of patients 
expected to begin TE therapy was highest in year 1 (19.8).
3.1.2  Costs
Table 4 shows a full breakdown of costs over 5 years in 
the world-without TE and world-with TE scenarios. The 
total cost in year 1 was €2,793,111 in the world-without TE 
Fig. 2  Markov model for treat-
ment response after the initial 
12-week treatment period. 
Patients with a durable response 
to TE begin the Markov process 
in the ‘SSA + TE’ arm. Patients 
who do not experience a 
durable response are assumed 
to discontinue TE but maintain 
SSA treatment and start in the 
‘SSA only’ arm. The transi-
tion between durable response 
and inadequate response in the 
SSA + TE arm was set to 0 for 
the base-case analysis. There 
were no deaths during the first 
12 weeks of the model (the 
trial period). CaHD carcinoid 
heart disease, SSA somatostatin 
analogue, TE telotristat ethyl
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scenario and €2,859,606 in the world-with TE scenario and 
subsequently declined over the 5-year period. The world-
with TE scenario resulted in total drug costs €269,056 
higher than in the world-without TE scenario over the 5-year 
period. Approximately 40% was offset by the reduced costs 
for other aspects of patient care in the world-with TE sce-
nario, including medical and surgical interventions, exami-
nations and imaging, outpatient visits, inpatient admissions, 
chemotherapy, other diarrhoea therapy and CaHD drug costs 
(Table 4).
The cumulative 5-year net budget impact of introduc-
ing TE to the current standard of care was €172,346; the 
cumulative cost over 5 years of treatment was €13,263,595 
for the world-without TE scenario and €13,435,941 for the 
world-with TE scenario (Table 5). The net budget impact 
per year of introducing TE to the current standard of care 
was predicted to decrease from €66,495 in year 1 to €29,818 
in year 5.
3.2  Deterministic Sensitivity Analyses
Results of the deterministic sensitivity analysis are shown 
in Fig. 3. The 5-year net budget impact of TE was most 
sensitive to the proportion of patients who continued TE 
therapy after 12 weeks of treatment despite lack of dura-
ble response. If 50% of patients who did not achieve a 
durable response continued TE therapy, the cumulative 
budget impact would increase to €696,661. The price of 
TE (250 mg) was the second biggest factor affecting the 
model outcomes, with a 25% increase or decrease resulting 
in a 5-year cumulative net budget impact of €251,668 and 
€92,824, respectively.
4  Discussion
Despite most patients with NETs receiving SSA therapy, 
many of those with CS continue to experience uncontrolled 
symptoms [24, 28, 30, 31, 52]. TE offers an effective, novel 
treatment option for patients with CS with uncontrolled diar-
rhoea. Used in combination with SSAs, TE has been shown 
to offer effective relief from CS diarrhoea and to improve the 
quality of life in patients who experience a durable response 
to treatment [38]. This study investigated the budget impact 
of the addition of TE to the current standard of care for CS 
in Sweden.
The total cost per year of treatment for patients with CS 
inclusive of TE therapy in Sweden declined over the 5-year 
time-period, from €2,859,606 in year 1 to €2,523,961 in year 
5, as patients were assumed to discontinue TE due to adverse 
events, lack of effectiveness and CS progression. The cumu-
lative 5-year net budget impact resulting from the addition of 
TE was relatively low at €172,346, with a per-year net cost 
of €66,495 in year 1 and decreasing thereafter.
The relatively low budget impact of adding TE to the 
existing standard of care in Sweden is likely due to two rea-
sons. First, CS is a component of a rare disease, and the 
number of total prevalent and incident patients eligible for 
TE was estimated at approximately 80 patients each year 
over the 5 years; according to market share assumptions, 
only 44 patients would initiate treatment with TE by year 
5. This aligns with findings from a 2014 study assessing 
the budget impact of orphan medicinal products in Swe-
den and France, in which the low overall number of annual 
sales made the costs associated with these treatments sus-
tainable [53]. Further to this, the TE budget impact model 
assumed that patients who responded to TE would gradually 
discontinue treatment either as the disease progressed, TE 
Table 3  Number of patients 
initiating TE treatment in the 
world-with TE scenario over 5 
years
Numbers may not sum due to rounding
TE telotristat ethyl
a TE was granted marketing authorisation in the EU prior to the start of year 1; therefore, prevalent patients 
were assumed to have had an opportunity to switch to TE in year 1 but were not expected to switch in fol-
lowing years
Year 1 (2018) Year 2 (2019) Year 3 (2020) Year 4 (2021) Year 5 (2022)
Prevalent cases 17.3a 0.0 0.0 0.0 0.0
Incident cases 2.5 5.3 5.9 6.1 7.2
Total cases 19.8 5.3 5.9 6.1 7.2
Number of patients 
discontinuing TE after 
initial 12-week treat-
ment period
14.9 4.0 4.5 4.6 5.4
Number of patients con-
tinuing TE after initial 
12-week treatment 
period
4.8 1.3 1.4 1.5 1.7
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Table 4  Total costs over 5 years from the world-without TE and world-with TE scenarios
CaHD carcinoid heart disease, IFN interferon, SSA somatostatin analogue, TE telotristat ethyl
Year 1 (2018) Year 2 (2019) Year 3 (2020) Year 4 (2021) Year 5 (2022) Total
World-without TE scenario
 Total costs, € 2,793,111 2,742,376 2,659,435 2,574,530 2,494,143 13,263,595
  SSA + TE drug costs 1,565,879 1,534,877 1,486,779 1,438,271 1,392,723 7,418,528
    TE 250 mg – – – – – –
    SSA only 1,565,879 1,534,877 1,486,779 1,438,271 1,392,723 7,418,528
    SSA component of TE arm – – – – – –
  Medical and surgical intervention 509,755 503,360 490,013 475,535 461,403 2,440,068
  Examinations and imaging 273,139 269,564 262,319 254,508 246,908 1,306,438
  Other outpatient visits 76,812 74,965 72,402 69,907 67,612 361,698
  Inpatient admissions 271,369 265,792 257,330 248,851 240,919 1,284,260
  IFN-α 86,157 83,998 81,069 78,239 75,648 405,112
  Chemotherapy 5752 5608 5413 5224 5051 27,048
  Other diarrhoea therapy 4224 4119 3975 3836 3709 19,863
  CaHD drug cost 25 93 134 158 170 580
World-with TE scenario
 Total costs, € 2,859,606 2,766,700 2,684,974 2,600,700 2,523,961 13,435,941
  SSA + TE drug costs 1,652,700 1,580,473 1,531,252 1,482,313 1,440,846 7,687,584
    TE 250 mg 97,334 56,542 54,083 52,965 57,136 318,061
    SSA only 1,190,068 1,112,025 1,017,163 927,248 828,840 5,075,343
    SSA component of TE arm 365,299 411,906 460,005 502,101 554,870 2,294,180
  Medical and surgical intervention 495,791 488,730 476,947 463,149 448,672 2,373,289
  Examinations and imaging 265,728 261,801 255,387 247,938 240,155 1,271,009
  Other outpatient visits 76,139 74,268 71,790 69,336 67,032 358,566
  Inpatient admissions 271,221 265,648 257,235 248,802 240,904 1,283,811
  IFN-α 88,295 86,243 83,093 80,182 77,667 415,480
  Chemotherapy 5567 5415 5241 5061 4883 26,167
  Other diarrhoea therapy 4139 4030 3896 3762 3633 19,461
  CaHD drug cost 24 91 133 156 168 574
Table 5  Costs and net budget 
impact of TE for the world-
without TE and world-with TE 
scenarios
PMPM per population member per month, PPPM per patient per month, TE telotristat ethyl
Year 1 (2018) Year 2 (2019) Year 3 (2020) Year 4 (2021) Year 5 (2022) Total
World-without TE scenario
 Total costs, € 2,793,111 2,742,376 2,659,435 2,574,530 2,494,143 13,263,595
 PMPM, € 0.02 0.02 0.02 0.02 0.02 –
 PPPM, € 2825 2723 2727 2729 2731 –
World-with TE scenario
 Total costs, € 2,859,606 2,766,700 2,684,974 2,600,700 2,523,961 13,435,941
 PMPM, € 0.02 0.02 0.02 0.02 0.02 –
 PPPM, € 2892 2747 2752 2756 2763 –
Net budget impact of TE
 Total costs, € 66,495 24,323 25,539 26,171 29,818 172,346
 PMPM, € 0.00 0.00 0.00 0.00 0.00 –
 PPPM, € 67.26 24.06 25.74 26.85 31.29 –
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effectiveness decreased, adverse events occurred or patients 
died, which would also contribute to the small economic 
impact.
Second, the improved diarrhoea symptom control result-
ing from treatment with TE translated into overall health-
care system cost savings that offset the pharmacy cost of 
TE, an outcome previously reported for other treatments 
in rare chronic diseases [54, 55]. Although patients who 
respond to TE will still require ongoing monitoring for 
tumour progression, they would avoid the increased costs 
related to uncontrolled CS. The total costs per patient per 
year associated with medical and surgical interventions, 
examinations and imaging, outpatient visits, inpatient 
admissions, chemotherapy and other diarrhoea thera-
pies were lower in the world-with TE scenario. This is in 
accordance with other studies showing that patients with 
CS who experience flushing and diarrhoea symptoms incur 
around $US14,766–29,890 more per year in healthcare 
costs than those experiencing improvements in symptoms 
[10, 56].
Our results are consistent with those from a US study that 
also showed a minimal budget impact on a US health plan 
of adding TE to SSA therapy [57]. In this study, the budget 
impact of adding TE totalled $US687,330 over 3 years. With 
a similar assumed market share (28% in year 1, 42% in year 
2, and 55% in year 3), the net annual overall healthcare cost 
of TE ($US55–109 million) was well under the Institute for 
Clinical and Economic Review (ICER) threshold for new 
molecular entities ($US915 million per year) when the study 
was published in 2017 [57]. While the ICER decreased the 
threshold to $US819 million in May 2019, the budget impact 
of adding TE to the standard of care in the USA still falls 
well under this amount [58].
A limitation of our study was the lack of readily available 
data, which is often a challenge when conducting budget 
impact analyses of treatments for orphan diseases [59, 60]. 
For example, prevalence and incidence data specific to Swe-
den were not available, so this analysis used data from a 
systematic review conducted for Europe and the USA to esti-
mate the size of the target population [44]. The derivation 
of cost inputs for patients with controlled and uncontrolled 
CS from Swedish databases presented another limitation 
for this study. It was assumed that patients demonstrating a 
durable response to TE would have the same resource use 
as patients with controlled CS, and patients without a dura-
ble response to TE would have that of patients with uncon-
trolled CS (despite the fact that the definition of a durable 
response relates to reductions in symptoms of diarrhoea). 
The impact of this assumption on our budget impact estimate 
is unknown. However, because diarrhoea is the most burden-
some symptom of CS, this model focused on cost outcomes 
associated with this symptom, though durable responders 
have also been shown to have improvements in other symp-
toms that would not be captured by this model [39]. It should 
be noted that this model does not account for the lost pro-
ductivity to individual patients and society in general from 
the impact of CS on quality of life and consequences such 
as missed workdays.
5  Conclusions
Treatment with TE alongside SSAs more often results in 
durable improvement of diarrhoea symptoms than use of 
SSAs alone; symptomatic relief can lead to improved quality 
of life for patients with NETs and CS. This budget impact 
model demonstrated that TE could be an affordable addition 
(13–22%); BC: 17%
(0.09–0.04); BC: 0.06
% failure to discontinue TE despite lack of efficacya
Net budget impact, €
0 100,000 200,000 400,000 500,000
Price of TE dose (€)b
% with CS inadequately controlled by SSAs
% with intestinal (small bowel) NETs
% with CS and grade 1/2 intestinal (midgut) NETs
HRU medical and surgical interventions, number/month, uncontrolled CS
HRU SSAs, number/month, uncontrolled CS
HRU inpatient admissions, number/month, uncontrolled CS
HRU SSAs, number/month, controlled CS
HRU inpatient admissions, number/month, controlled CS
























Lower estimates for value Upper estimates for value
000,007000,006000,003 800,000
Fig. 3  Deterministic sensitivity analyses on the 5-year net budget 
impact. aFailure to discontinue treatment with TE after 12 weeks of 
TE treatment using data from TELESTAR. bParameter varied based 
on arbitrary ranges. Values in parentheses are the variation param-
eters for the sensitivity analyses. BC base case, CS carcinoid syn-
drome, HRU healthcare resource use, NET neuroendocrine tumour, 
SSA somatostatin analogue, TE telotristat ethyl
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to the current standard of care for patients with NETs and CS 
in Sweden. Therefore, further research assessing the health 
and budget impacts of TE and other treatments for CS and 
NETs in Sweden would be beneficial and is warranted.
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